Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET C634W |
| Therapy | MitoQ + Selpercatinib |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET C634W | medullary thyroid carcinoma | sensitive | MitoQ + Selpercatinib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Retevmo (selpercatinib) and MitoQ synergistically inhibited viability of a medullary thyroid cancer cell line harboring RET C634W in culture (PMID: 38378752). | 38378752 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38378752) | Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer. | Full reference... |